iBio successfully expanded the use of its technology to biosimilar mAbs by producing rituximab in non-transgenic green plants, thereby expanding its use beyond production of viral antigens for vaccines.
"The production of functional rituximab in plants suggests that many if not all mAbs can be produced using the iBioLaunch system," says Terence Ryan, senior vice president.
iBio says that the rituximab produced in plants underwent a number of preclinical tests to evaluate efficacy. The plant-derived treatment showed similar target cell cytotoxicity and antigen recognition to rituximab produced in mammalian cells. No word if the products were compared under similar guidelines used by the EMEA to judge a biosimilar versus the approved reference product -- or not.
Posted by Bruce Lehr Oct 10th 2011.